217 related articles for article (PubMed ID: 35924258)
1. Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness.
Zhao W; Yang S; Li C; Li F; Pang H; Xu G; Wang Y; Cong M
Int J Nanomedicine; 2022; 17():3239-3249. PubMed ID: 35924258
[TBL] [Abstract][Full Text] [Related]
2. Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy.
Cong M; Pang H; Xie G; Li F; Li C; Sun H; Yang S; Zhao W
Int J Nanomedicine; 2023; 18():6367-6377. PubMed ID: 37954452
[TBL] [Abstract][Full Text] [Related]
3. An Amphiphilic PEGylated Peptide Dendron-Gemcitabine Prodrug-Based Nanoagent for Cancer Therapy.
Li N; Duan Z; Wang L; Guo C; Zhang H; Gu Z; Gong Q; Luo K
Macromol Rapid Commun; 2021 Jun; 42(12):e2100111. PubMed ID: 33871122
[TBL] [Abstract][Full Text] [Related]
4. Half generations magnetic PAMAM dendrimers as an effective system for targeted gemcitabine delivery.
Parsian M; Mutlu P; Yalcin S; Tezcaner A; Gunduz U
Int J Pharm; 2016 Dec; 515(1-2):104-113. PubMed ID: 27725272
[TBL] [Abstract][Full Text] [Related]
5. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
[TBL] [Abstract][Full Text] [Related]
6. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z
Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838
[TBL] [Abstract][Full Text] [Related]
8. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells.
Kakwere H; Ingham ES; Tumbale SK; Ferrara KW
Mater Sci Eng C Mater Biol Appl; 2020 Dec; 117():111251. PubMed ID: 32919625
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
11. Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines.
Yalçin S; Erkan M; Ünsoy G; Parsian M; Kleeff J; Gündüz U
Biomed Pharmacother; 2014 Jul; 68(6):737-43. PubMed ID: 25108345
[TBL] [Abstract][Full Text] [Related]
12. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
13. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
14. Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer.
Liu J; Chen C; Wei T; Gayet O; Loncle C; Borge L; Dusetti N; Ma X; Marson D; Laurini E; Pricl S; Gu Z; Iovanna J; Peng L; Liang XJ
Exploration (Beijing); 2021 Aug; 1(1):21-34. PubMed ID: 37366462
[TBL] [Abstract][Full Text] [Related]
15. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance.
Wei T; Chen C; Liu J; Liu C; Posocco P; Liu X; Cheng Q; Huo S; Liang Z; Fermeglia M; Pricl S; Liang XJ; Rocchi P; Peng L
Proc Natl Acad Sci U S A; 2015 Mar; 112(10):2978-83. PubMed ID: 25713374
[TBL] [Abstract][Full Text] [Related]
16. A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.
Dong Y; Yu T; Ding L; Laurini E; Huang Y; Zhang M; Weng Y; Lin S; Chen P; Marson D; Jiang Y; Giorgio S; Pricl S; Liu X; Rocchi P; Peng L
J Am Chem Soc; 2018 Nov; 140(47):16264-16274. PubMed ID: 30346764
[TBL] [Abstract][Full Text] [Related]
17. A biocompatible and cathepsin B sensitive nanoscale system of dendritic polyHPMA-gemcitabine prodrug enhances antitumor activity markedly.
Dai Y; Ma X; Zhang Y; Chen K; Tang JZ; Gong Q; Luo K
Biomater Sci; 2018 Nov; 6(11):2976-2986. PubMed ID: 30255871
[TBL] [Abstract][Full Text] [Related]
18. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.
Elechalawar CK; Hossen MN; Shankarappa P; Peer CJ; Figg WD; Robertson JD; Bhattacharya R; Mukherjee P
Int J Nanomedicine; 2020; 15():991-1003. PubMed ID: 32103952
[TBL] [Abstract][Full Text] [Related]
19. Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors.
Garrigue P; Tang J; Ding L; Bouhlel A; Tintaru A; Laurini E; Huang Y; Lyu Z; Zhang M; Fernandez S; Balasse L; Lan W; Mas E; Marson D; Weng Y; Liu X; Giorgio S; Iovanna J; Pricl S; Guillet B; Peng L
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):11454-11459. PubMed ID: 30348798
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody.
Yoyen-Ermis D; Ozturk K; Kursunel MA; Aydin C; Ozkazanc D; Gurbuz MU; Uner A; Tulu M; Calis S; Esendagli G
Mol Pharm; 2018 Apr; 15(4):1526-1533. PubMed ID: 29481086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
